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  BACKGROUND: About 2-5% of people experience deep-vein thrombosis (DVT) during their 
lives. Death, disease recurrence, post-thrombotic syndrome, and excessive bleeding due to coa-
gulant medications are among the most important DVT complications. Recent research found a 
high incidence of DVT recurrence after the first attack. Disease recurrence has a multifactorial 
pathogenesis and its probability is related with the number and severity of risk factors. The 
present study aimed to investigate DVT recurrence and the associated risk factors. 
 METHODS: This retrospective cross-sectional study evaluated all DVT patients hospitalized in 
Alzahra Hospital, Isfahan, Iran, during April 2000 to April 2011. The risk factors were obtained 
from patients' records including smoking, intravenous drug abuse, having a history of surgery in 
last four weeks, immobility, obesity, history of cardiac disease, and cancer. 
 RESULTS:  A total number of 2550 DVT patients were hospitalized in Alzahra Hospital during 
the study period. It was only possible to extract the data from 385 patient records. A history of 
DVT was reported in 48 individuals (12.5%). The comparison between the risk factors in pa-
tients with a first time DVT and those experiencing a recurrent DVT revealed significant differ-
ences solely in the prevalence of blood disorders and immobility. Applying stepwise regression 
indicated immobility (OR: 4.57; 95% CI: 1.26-16.57; P < 0.021) and coagulopathy (OR: 0.33; 
95% CI: 0.13-0.81; P < 0.016) with DVT recurrence. 
  CONCLUSION: Based on our findings, DVT patients are suggested to be mobilized as soon as 
possible. In addition, they should be advised to increase their activity after discharge. 
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Introduction 
Venous thromboembolism (VTE) is the third common 
vascular disease after coronary artery disease and stroke 
which is experienced by 2-5% of people during their 
lifetime. The condition occurs in two forms of   
deep-vein thrombosis (DVT) and pulmonary embolism 
(PE).1-4 The annual rate of DVT with organ 
involvements in urban areas is reported to be 0.5-1.6 in 
every 1000 people which is probably much higher in 
reality due to asymptomatic forms of the disease.5,6 The 
risk for DVT increases with age, i.e. while only 5 out of 
every 100,000 children suffer the problem, the rate 
increases to 400 out of every 100,000 in people over 80.7 
Typically, DVT starts with an acute pain, redness 
and swelling from the calf to the thigh. A clear swel-
ling in the rear thigh with tenderness along the deep 
venous system is observed in examination. Howev-
er,in most cases the condition is asymptomatic and 
silent and heals spontaneously and without treament.8 
DVT risk factors include aging over 40, obesity, 
immobilization especially after long journeys, history 
of hypercoagulation, genetic factors leading to 
thrombophilia, certain blood diseases, cancer, heart 
failure, bone fractures, smoking and recent surgeries. 
In women, however, oral contraceptive pills (OCPs) 
and hormone replacement therapy (HRT) are also 
among the main risk factors. In addition, idiopathic 
form of the disease is not uncommon.9 
Death, disease recurrence, post-thrombotic syn-
drome, and severe bleedings are the most important 
side effects of anticoagulation medicines used for 
DVT.10,11 A mortality rate of 6% has been reported in 
the first six months after the disease onset.12 Recent 
studies found a high incidence of recurrent DVT 
(RDVT) with half of DVT incidences in the U.S be-
ing the disease recurrence.13-18 A relapse after a five-
year disease free interval is observed in 20-30% of the 
patients.19,20 While some studies reported the annual The predictive factors of recurrent deep 
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incidence rate of the first recurrent attack to be 3-5%, 
which is generally most probable to happen during the 
first two years after the discontinuation of   
anticoagulation treatment, others claimed a higher rate 
of 5-10%.19,21,22 The incidence of disease recurrence, as 
a condition with a multifactorial pathogenesis, is related 
with the number and severity of the risk factors. In a 
study conducted in Norway, cancer, previous proximal 
DVT and previous VTE were suggested to be major 
factors causing RDVT. In addition, although the con-
dition is more prevalent among men, many studied did 
not indicate sex as a risk factor for DVT recurrence.19 
The present study aimed to investigate the   
incidence of DVT during 10 years in the main VTE 
referral center in Isfahan, Alzahra Hospital, and also 
to find the frequency of reoccurrence and its   
associated risk factors. 
Materials and Methods 
This retrospective cross-sectional study investigated 
all DVT inpatients in Alzahra Hospital during April 
2000-April 2011. Patient records were collected from 
the hospital archive. Patients with incomplete records 
were excluded. The diagnosis was made based on 
clinical symptoms, existing risk factors and Doppler 
sonography.  
Demographics, DVT risk factors, clinical symptoms, 
treatment method, history of DVT, previous treatment 
for DVT and hospitalization duration were studied in 
this research. The risk factors included smoking, drug 
injection, a history of surgery during the last 4 weeks, 
immobilization, obesity, history of cardiovascular   
diseases, coagulopathy and cancer. In women, however, 
additional factors of the history of recent pregnancy, 
hormone replacement therapy (HRT) and oral   
contraceptive pill (OCP) usage were also considered.  
The data was analyzed in SPSS version 19.   
Frequency of risk factors, treatment method (percent) 
and average hospitalization duration (mean ± SD) 
were calculated. Student's t-test and chi-square test 
were used to evaluate the risk factors in patients with 
a history of DVT compared with those experiencing 
the condition for the first time (FDVT). In order to 
determine the effective factors in disease recurrence, 
logistic regression test was employed to calculate odds 
ratio (OR). A P-value lower than 0.05 was considered 
statistically significant. 
 Results 
Out of a total number of 2550 patients hospitalized 
due to DVT during the 11 studied years in Alzahra 
Hospital, only 385 records were extractable. The av-
erage age among the subjects [228 men (59.2%)], was 
48.30 ± 19.16 years. No risk factor was found in 35 
individuals (9.1%). Most involvements were seen in 
left leg, in 229 cases alone (59.5%) and in 13 cases 
with right leg involvements (3.4%). Moreover, the 
average hospitalization duration was 7.23 ± 5.48 days.  
 
Table 1. The comparison of participants’ baseline demographic and risk factors between two groups 





n(%)  P value 
n 385(100)  337(87.5)  48(12.5)   
Age (years)*  48.30 ± 19.16  48.79 ± 19.26  44.83 ± 18.28  0.180† 
Sex (men)  228(59.2)  200(59.3)  137(40.7)  0.894†† 
Family history  5(1.3)  4(1.2) 1(2.1)  0.488††† 
Coagulopathy 12(3.1)  8(2.4)  4(8.3)  <0.050†† 
Immobilization 102(26.5)  96(28.5)  6(12.5)  0.019†† 
smoking 99(25.7)  88(26.1)  11(22.9)  0.635†† 
surgery 53(13.8)  48(14.2)  5(10.4)  0.472†† 
Pelvic 9(2.3)  9(2.7)  0 
0.837††  Knee 2(0.5)  2(0.6)  0 
Others 42(10.9)  37(11.0)  5(10.4) 
Obesity 7(1.8)  6(1.8) 1(2.1)  1.000††† 
Cancer 20(5.2)  18(5.3)  2(4.2)  1.000††† 
Contraceptive 38(9.9)  36(10.7)  2(4.2)  0.200††† 
HRT 3(0.8)  3(0.9)  0  1.000††† 
CVD treatment  17(4.4)  15(4.5)  2(4.2)  0.643 
IV drug abuse  32(8.3)  29(8.6)  3(6.3)  0.782†† 
Pregnancy 8(2.1)  6(1.8) 2(4.2)  0.262†† 
DVT: Deep vein thrombosis; HRT: Hormone replacement therapy 
* Mean ± Standard Deviation; † Student’s t-test 
†† Chi-square; †††Fisher’s exact test    H. Farzamnia, K. Rabiei, M. Sadeghi, F. Roghani 
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A previous history of DVT existed in 48 subjects 
(12.5%). Table 1 represents a comparison between 
demographics and risk factors in FDVT and RDVT 
groups. As this table shows, although the FDVT 
group had a higher age, the difference was not   
significant. In addition, sex distribution in the two 
groups was similar. The only significant difference 
among the two groups was observed in the frequency 
of coagulopathy and immobilization. 
Table 2 compares the clinical symptoms, treatment 
method, and hospitalization duration in FDVT and 
RDVT groups. Based on this table, swelling was   
significantly more in FDVT patients than in RDVT 
subjects. In addition, the hospitalization duration was 
significantly shorter in RDVT group. 
Table 3 represents the model applied to determine 
the risk factors of RDVT. This model was designed 
based on regression test using enter method and   
included all demographics and risk factors. As shown 
in this table, the calculated odds ratio (OR) was only 
significant in coagulopathy, immobilization and CVD 
treatment. Stepwise regression analysis found only 
immobilization (OR: 4.57; 95% CI: 1.26-16.57; 
P < 0.021) and coagulopathy (OR: 0.33; 
95% CI: 0.13-0.81; P < 0.016) to have a significant 
relation with RDVT. 
 
Table 2. The comparison of participants’ sign and symptoms and the method of treatment between two groups 





n(%)  P value 
Site       0.867†† 
Left Leg  229 (59.48)  202 (59.94)  27 (56.25) 
  Right Leg  143 (37.14) 124 (36.79) 19 (39.58) 
Both  13 (3.37)  11 (3.26)  2 (4.16) 
Swelling 374(97.1) 331(98.2) 43(89.6)  0.006††
pain 326(84.7)  288(85.5)  38(79.2)  0.117†† 
Tenderness 116(30.1)  98(29.1)  18(37.5)  0.234†† 
Warmness 180(46.8) 163(48.4) 17(35.4)  0.092††
Erythema 93(24.2)  77(22.8)  16(33.3)  0.112†† 
Bulging 6(1.6)  4(1.2) 2(4.2)  0.165†† 
fever 27(7.0) 26(7.7) 1(2.1)  0.227††
treatment        
Heparin + warfarin  318(82.6)  275(81.6)  43(89.6) 
0.642†† 
Heparin 22(5.7)  20(5.9)  2(4.2) 
Enoxaparin 2(0.5)  2(0.6)  0(0) 
Enoxaparin + warfarin  27(7.0) 24(7.1)  3(6.3) 
Enoxaparin + warfarin + Heparin  16(4.2)  16(4.7)  0(0) 
Hospital stay (days) *  7.23 ± 5.48  7.43 ± 5.74  5.77 ± 2.64  0.049† 
DVT: Deep vein thrombosis; * Mean ± Standard deviation;  
† Student’s t-test; †† Chi-square  
 
Table 3. The effect of risk factors on the recurrence of deep vein thrombosis 
Variable OR  P  value 
Age (years)  0.612  0.434 
Sex(men) 0.078  0.779 
Family history  0.050  0.823 
coagolopathy 0.331  <0.016 
Immobilization 4.570  <0.021 
smoking 0.569  0.451 
surgery 0.019  0.891 
obesity 0.013  0.908 
Cancer 0.073  0.787 
HRT 0.276  0.600 
CVD treatement  0.001  0.971 
IV drug abuse  0.604  0.437 
Pregnancy 1.050  0.305 
HRT: Hormone replacement therapy 
CVD: Coronary vascular disease The predictive factors of recurrent deep 
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Discussion 
The prevalence of DVT among men and individuals 
over 40 years was more than that among women and 
people below 40. In addition, the third important risk 
factor (after age and sex) was immobilization. 
The regression model showed a significant   
difference between immobilization and coagulation 
disorders in patients with first and recurrent DVT. 
Although immobilization was more common among 
FDVT patients, stepwise regression showed a   
significant association between immobilization and 
RDVT (OR = 4.570). Moreover, hospitalization   
duration and swelling frequency were significantly less 
common in RDVT subjects. Kyrle et al. followed 826 
patients for 36 months after the first DVT and   
observed the disease recurrence in 20% of men and 
6% of women. Their results indicated a significant 
relationship between sex and disease recurrence   
(RR 3.6, 95% CI 2.3-5.5, P < 0.001).23 
In a meta-analysis conducted on 7 prospective   
researches, Douketis et al. studied 2554 subjects who 
were followed for an average of 27.1 months and 
suggested that compared to women, men were 2.2 
times more likely to experience a recurrent VTE after 
their first DVT. Even after adjusting the model based 
on HRT in women, recurrent DVT was 1.8 times 
more common among men.24 Unlike some previous 
studies, our findings did not suggest any relation   
between sex and DVT recurrence (maybe because 
this was a retrospective study conducted on patients 
with RDVT). 
Cushman et al. studied the occurrence of DVT 
and pulmonary embolism in 21680 subjects over 45 
years that participated in two cohort studies, namely 
Atherosclerosis Risk in Communities and the   
Cardiovascular Health Study. The subjects were   
followed for 7 years. First VTE rate was 1.92 out of 
1000. The condition was more prevalent among men 
and its occurrence increased with age. The annual 
recurrence rate during the 2-year period after the first 
VTE was 7.7 and the only reason for the disease   
recurrence was cancer (RR 9.2, 95% CI 2.0-41.7).12 
In a cohort study, Hansson et al. followed 738   
patients with DVT for 3.7-8.8 years and found the 
cumulative incidence of recurrent VTE to be 21.5% 
in 5 years. Their multivariate survival analysis revealed 
proximal DVT, cancer and previous history of 
thromboembolism to be independent risk factors for 
the VTE recurrence. They did not find any significant 
relations between age, sex, antithrombotic treatment 
or immobilization and disease recurrence.19 In   
another study, White et al. followed 37000 patients 
with DVT for 6 months and suggested that DVT   
recurrence is related with age, cancer, surgeries and 
hospitalization duration.18  
A clinical trial conducted by Schulman et al.   
followed 897 subjects, divided into two groups 
receiving vitamin antagonist for 6 weeks and 6 
months for ten years, respectively. Regardless of the 
intervention group, disease recurrence was seen in 
29.1% of all patients. This study found a significant 
association between disease recurrence and high age, 
being male, persistent risk factors especially venous 
insufficiency at baseline, proximal DVT, pulmonary 
embolism, and symptoms of impaired venous 
circulation disorder at the time of release.25 
In 2005, Partsch reviewed the studies on acute 
DVT recurrence and reported that some studies sug-
gested immobilization or restricted physical activity as 
important factors in disease recurrence. In addition, 
the same studies recommended walking accompanied 
with an appropriate compression on the involved site 
during the treatment period. His results indicated that 
immobilization, as one of Virchow's triad criteria, may 
cause venous stasis.26  Prandoni et al. conducted a 
study on 377 DVT patients and found recurrent DVT 
associated with immobilization. Similar to Partsch 
inference, they also suggested quick mobilization of 
the patients and increasing their physical activity after 
the first DVT as a good treatment method.3 
Several studies conducted on the relation between 
DVT recurrence and its associated risk factors includ-
ing age, sex, cancer, bone fractures, hip and knee sur-
geries, proximal DVT, immobilization and coagula-
tion disorders. However, these studies were most 
prospective and included patients with FDVT. Unlike 
the mentioned researches, our study did not find any 
significant relation between RDVT and cancer, age, 
surgery, sex, and proximal DVT. However, our results 
revealed the strong effect of immobilization on 
RDVT. In addition, numerous studies suggested coa-
gulation disorders to be one of the most important 
factors causing DVT, either for the first time or as a 
recurrent disease. We could not prove coagulopathy 
as a risk factor. The reason might have been the care 
individuals with a history of disorders paid to their 
treatment. In other words, the concurrence of such 
disorders and a DVT incidence caused the patients to 
commit to treatment. Therefore, to our surprise, coa-
gulopathy actually appeared as a preventive factor. A 
further prospective study would be beneficial in clear-
ly understanding the issue. 
The high rate of intravenous (IV) drug abusers 
(8.3%) among the patients in the present study was 
also noticeable. Previous studies on drug addicts   
suggested DVT as a complication caused by drug 
abuse (especially IV drug abuse). Mohammadzadeh et   H. Farzamnia, K. Rabiei, M. Sadeghi, F. Roghani 
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al. studied 50 IV drug abusers in Northern Iran and 
indicated pseudo aneurysm with a frequency of 52% 
as the most common vascular complication among 
these subjects. DVT was the next common   
complication with a frequency of 18%.27 Yegane et al. 
studied the effect of surgery on 62 IV drug abusers 
complaining from tenderness and swelling in the 
groin region and noted a high rate of DVT (50%) 
among these patients.28 
In a case-control study, Masoomi et al. compared 
DVT patients with healthy subjects in central Iran 
(Kerman). They showed that in the regression model, 
the crude effect of opium addiction on DVT was very 
strong (OR 4.25, 95% CI 2.6-6.9). However, the   
effect was eliminated after multivariate regression 
analysis (OR 0.56, 95% CI 0.1-3).29 
Based on the results from the present study,   
increased physical activity is recommended to indi-
viduals with long periods of immobilization. If the 
patient is able to move after the first DVT, they are 
suggested to start mobilization quickly and to be 
physically active during long haul flights. Moreover, 
considering the relationship between coagulation   
disorders and disease recurrence, an appropriate   
antithrombotic treatment would be necessary. 
This was a retrospective study based on the   
information that patients provided for their   
physicians. A prospective study can follow the   
patients with first DVT and exactly record the risk 
factors and treatment methods applied to determine 
their effects on disease recurrence. Another point to 
keep in mind is to educate IV drug abusers about   
methods preventing thrombosis and the associated   
complications. 
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